Abstract
Objective:
Selective internal radiation therapy (SIRT) using SIR-Spheres® 90Y-labeled resin microspheres has been shown to be a well-tolerated, effective treatment in patients with inoperable liver-dominant chemotherapy–refractory metastatic colorectal cancer (mCRC). This study estimated the cost-effectiveness of 90Y-resin microspheres compared to best supportive care (BSC) from a UK perspective.
Methods:
Survival data from a comparative retrospective cohort study was analyzed and used in a state-transition cost-effectiveness model, using quality-adjusted life years (QALYs) gained as the measure of effectiveness. The model incorporated costs for the SIRT procedure, monitoring, further treatment, adverse events, and death. Utility values, reflecting patient quality-of-life, were taken from a published source.
Results:
SIRT using 90Y-resin microspheres compared to BSC improved overall survival by a mean of 1.12 life years and resulted in a cost per QALY gained of £28,216. In sensitivity analysis, this varied between £25,015–£28,817.
Conclusion:
In an area of large unmet need, treatment with 90Y-resin microspheres offers a clinically effective and cost-effective treatment option.
Transparency
Declaration of funding
The development of the economic model and the manuscript was funded by Sirtex Medical Limited, the manufacturer of SIR-Spheres.
Declaration of financial/other relationships
BP and RA work for BresMed, who were reimbursed by Sirtex Medical Limited for their time on preparing the manuscript. KS is an employee of Sirtex Medical Limited. LB, AK, BS, and HW act as advisors to Sirtex Medical Limited.
Acknowledgments
The authors would like to thank Nic Brereton for aiding in the design of the study and critiquing the manuscript, Baerbel Meteling for her assistance in providing the data, Becca Harvey for performing statistical analysis of the data, and Chris Knight for reviewing the manuscript.